View Older Stories View More Recent Stories
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
-
Vor Biopharma (VOR) Announces $175 Million Private Placement
-
Vor Bio Announces $175 Million Private Placement
-
Dignify Therapeutics Announces Jeff Welch as Chief Operating Officer
-
Form SCHEDULE 13D/A Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at
-
Navigator Medicines Announces First Participants Dosed in a Phase 1b Trial of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
-
New Study Reveals Agriculture as Largest, Most Resource-Intensive Industry on Earth
-
Form SCHEDULE 13D/A iTeos Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia
-
Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A GERON CORP Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Dyne Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A CHIMERIX INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A BRIGHT MINDS BIOSCIENCES Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Verona Pharma plc Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Adagio Medical Holdings, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Form SCHEDULE 13D/A iTeos Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Stylus Medicine Launches to Develop Precision, In Vivo Genetic Medicines and Unlock the Full Potential of CAR-T Therapy
-
Form SCHEDULE 13D/A LENZ Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Jade Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
-
Adela Presents Data Demonstrating Ability of Tissue-Free MRD Test to Predict Recurrence in Lung Cancer at the American Association for Cancer Research Annual Meeting 2025
-
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
-
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
-
Report: Washington State’s $41.2B Life Sciences Industry Grew 50% Over Past Decade
-
Adela's Co-Founder & Chief Scientific Officer, Dr. Daniel De Carvalho, Receives 2025 Canada Gairdner Momentum Award Recognizing World-Renowned Scientists for Exceptional Scientific Research Contri
-
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO
-
Form SCHEDULE 13G SUTRO BIOPHARMA, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Edgewise Therapeutics Inc. (EWTX) Announces Pricing of $200M Underwritten Offering of Common Stock
-
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
-
Form SCHEDULE 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Announces Five Presentations at American Association for Cancer Research (AACR) Annual Meeting
-
Surrozen (SRZN) Announces Oversubscribed $175M Private Placement
-
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
-
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
-
Form SCHEDULE 13D/A Mineralys Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
